Summary | |
---|---|
Symbol | WDR33 |
Name | WD repeat domain 33 |
Aliases | FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ...... |
Chromosomal Location | 2q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus |
Domain |
PF00400 WD domain |
Function |
Essential for both cleavage and polyadenylation of pre-mRNA 3' ends. |
Biological Process |
GO:0006301 postreplication repair GO:0006379 mRNA cleavage GO:0006397 mRNA processing GO:0007283 spermatogenesis GO:0048232 male gamete generation GO:0090305 nucleic acid phosphodiester bond hydrolysis GO:0090501 RNA phosphodiester bond hydrolysis |
Molecular Function | - |
Cellular Component |
GO:0005581 collagen trimer GO:0005847 mRNA cleavage and polyadenylation specificity factor complex GO:0005849 mRNA cleavage factor complex |
KEGG |
hsa03015 mRNA surveillance pathway |
Reactome |
R-HSA-109688: Cleavage of Growing Transcript in the Termination Region R-HSA-74160: Gene Expression R-HSA-112296: Post-Elongation Processing of Intron-Containing pre-mRNA R-HSA-112297: Post-Elongation Processing of Intronless pre-mRNA R-HSA-76044: Post-Elongation Processing of the Transcript R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA R-HSA-75067: Processing of Capped Intronless Pre-mRNA R-HSA-77595: Processing of Intronless Pre-mRNAs R-HSA-73857: RNA Polymerase II Transcription R-HSA-73856: RNA Polymerase II Transcription Termination R-HSA-72202: Transport of Mature Transcript to Cytoplasm R-HSA-159231: Transport of Mature mRNA Derived from an Intronless Transcript R-HSA-159234: Transport of Mature mRNAs Derived from Intronless Transcripts R-HSA-72187: mRNA 3'-end processing R-HSA-72172: mRNA Splicing R-HSA-72163: mRNA Splicing - Major Pathway |
Summary | |
---|---|
Symbol | WDR33 |
Name | WD repeat domain 33 |
Aliases | FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ...... |
Chromosomal Location | 2q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between WDR33 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | WDR33 |
Name | WD repeat domain 33 |
Aliases | FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ...... |
Chromosomal Location | 2q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of WDR33 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | WDR33 |
Name | WD repeat domain 33 |
Aliases | FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ...... |
Chromosomal Location | 2q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of WDR33 in various data sets.
|
Points in the above scatter plot represent the mutation difference of WDR33 in various data sets.
|
Summary | |
---|---|
Symbol | WDR33 |
Name | WD repeat domain 33 |
Aliases | FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ...... |
Chromosomal Location | 2q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of WDR33. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | WDR33 |
Name | WD repeat domain 33 |
Aliases | FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ...... |
Chromosomal Location | 2q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of WDR33. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by WDR33. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | WDR33 |
Name | WD repeat domain 33 |
Aliases | FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ...... |
Chromosomal Location | 2q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of WDR33. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | WDR33 |
Name | WD repeat domain 33 |
Aliases | FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ...... |
Chromosomal Location | 2q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of WDR33 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | WDR33 |
Name | WD repeat domain 33 |
Aliases | FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ...... |
Chromosomal Location | 2q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between WDR33 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | WDR33 |
Name | WD repeat domain 33 |
Aliases | FLJ11294; WDC146; NET14; WD repeat-containing protein 33; WD repeat-containing protein WDC146; pre-mRNA 3' e ...... |
Chromosomal Location | 2q21.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting WDR33 collected from DrugBank database. |
There is no record. |